Nucl Med Mol Imaging.
2007 Dec;41(6):525-529.
Suggestions for Radiopharmaceutical Drug Development in Korea Focusing on FDA Exploratory IND Guideline
- Affiliations
-
- 1Department of Nuclear Medicine, Yonsei University, Medical College, Seoul, Korea. ryuyh@yumc.yonsei.ac.kr
- 2Radiological and Medical Sciences Research Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Abstract
- Regulation for the radiopharmaceuticals should be reasonably different from that of other drugs. Radiopharmaceuticals are always used by compounding based on the doctor's order, have short half life and very low administration dose. Its pharmacological effect is not from its chemical effect but from radiation. The background for exploratory IND (Investigational New Drug) explained by the FDA was to reduce the time and resources expended on candidate products that are unlikely to suceed, new tools are needed to distinguish earlier in the process those candidates that hold promise from those that do not. In this review, basic concept for exploratory IND and RDRC guideline is summarized and various suggestions for improving and expediting procedure for new radiopharmaceutical development would be described.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Current Status of PSMA‑Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization
- Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels
- Clinical Trial for Antidiabetic Drugs: FDA Guidance for Diabetes Mellitus-Evaluation of Cardiovascular Risk in New Antidiabetic Therapies
- Summary and Recent Trends of Clinical Trials Processes in New Drug Development, and Changes of Relating Regulations
- FDA initiatives to support dose optimization in oncology drug development: the less may be the better
